Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study

Breast Cancer Research and Treatment(2025)10.1007/s10549-025-07795-3Source: DataRank Database

Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study is a research paper published in Breast Cancer Research and Treatment (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.00)OA: closedTopics (46)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

N Sridhar,Megumi Kai ORCID,Wenli Dong ORCID,Shen Yu ORCID,Savitri Krishnamurthy ORCID

Live enrichment

PubMed:40753318 OpenAlex:https://openalex.org/W4412862409

National Institutes of Health

Grant: P30CA016672

National Institutes of Health

Grant: 1R01CA205043-01A1

FWCI

0.00

Citation Percentile

0.1%

closedLicense: https://www.springernature.com/gp/researchers/text-and-data-mining

publisherhttps://link.springer.com/content/pdf/10.1007/s10549-025-07795-3.pdf

publisherhttps://link.springer.com/article/10.1007/s10549-025-07795-3/fulltext.html

journalhttps://doi.org/10.1007/s10549-025-07795-3

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40753318

Fields of Study

Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchBreast Lesions and CarcinomasHumansFemaleInflammatory Breast NeoplasmsNeoadjuvant TherapyMiddle AgedErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesAnthracyclinesAdultAgedTreatment OutcomeTrastuzumabDoxorubicin

MeSH Terms

TrastuzumabAdultAgedAntineoplastic Combined Chemotherapy ProtocolsDoxorubicinFemaleHumansMiddle AgedRetrospective StudiesTreatment OutcomeReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesAnthracyclinesNeoadjuvant TherapyInflammatory Breast Neoplasms

Keywords

MedicineBreast cancerInflammatory breast cancerOncologyInternal medicineRetrospective cohort studyChemotherapyNeoadjuvant therapyMulticenter studyCancerRandomized controlled trialAnthracyclinesInflammatory breast neoplasmsPertuzumab

Sustainable Development Goals

SDG 0: Good health and well-being

Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study

FAIR Checklist

Authors (19)

Funding (2 grants)

Impact

Open Access

Topics